Clinical Research Directory

Inclusion Criteria: * Male or Female, 18-65 years of age at the time of enrollment; * Ability to understand and provide written informed consent; * Candidate for primary renal allograft from either living or deceased donor; * No known contraindications to study therapy using NULOJIX® (belatacept); * Female participants of childbearing potential must have a negative pregnancy test upon study entry; * Participants with reproductive potential must agree to use an appropriate method(s) of birth control as outlined in the CellCept® , Myfortic® or generic package labeling during participation in the study and for 4 months following completion of the study; * No donor specific antibodies prior to transplant that are considered to be of clinical significance by the site investigator; * Negative crossmatch or Panel Reactive Antibodies (PRA) of 0% on historic and current sera, as determined by each participating study center; * A documented negative tuberculosis (TB) test within the 6 months prior to transplant. If documentation is not present at the time of transplantation, and the subject does not have any risk factors for TB, a TB-specific interferon gamma release assay (IGRA) may be performed. Exclusion Criteria: * Need for multi-organ transplant; * Recipient of previous organ transplant; * Epstein-Barr Virus (EBV) seronegative (or unknown) recipients; * Active infection including hepatitis B, hepatitis C, or human Immunodeficiency Virus (HIV); * Individuals who have required treatment with prednisone or other immunosuppressive drugs within 1 year prior to transplant; * Individuals undergoing transplant using organs from extended criteria donor (ECD) or donation after cardiac death (DCD) donors; * Histocompatibility antigen (HLA) identical living donors; * Individuals at significant risk of early recurrence of the primary renal disease including focal segmental glomerulosclerosis (FSGS) and membranoproliferative glomerulonephritis (MPGN) type 2 or any other disease that in the opinion of the investigator is at increased likelihood of recurrence and which may result in rapid decline in renal function; * Known history of thrombotic events or risk factors, including any of the following: * Factor V Leiden, elevated homocysteine, positive lupus anticoagulant, elevated anticardiolipin antibody, heparin-induced thrombocytopenia, * A family history of a heritable thrombotic condition, * Recurrent deep vein thrombosis (DVT) or pulmonary emboli (PE), * Unexplained stillborn infant or recurrent spontaneous abortion or other congenital or acquired thrombotic disorder. At the discretion of the investigator, a history of thrombosis of a dialysis access graft, fistula, or indwelling catheter/device may not be considered an exclusion criterion. * Any condition that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements; * Use of investigational drugs within 4 weeks of enrollment; * Known hypersensitivity to mycophenolate mofetil (MMF)or any of the drug's components; * Administration of live attenuated vaccine(s) within 8 weeks of enrollment; * Blood type A2 and A2B donors into blood type B recipients.